Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3209 | Quetiapine Wiki | 1.00 |
| drug4196 | Valproate Wiki | 1.00 |
| drug3728 | Standard of Care Wiki | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become pandemic. To date, no specific treatment has been proven to be effective. Promising results were obtained in China using Hyperimmune plasma from patients recovered from the disease.The investigators plan to treat critical Covid-19 patients with hyperimmune plasma.
Description: death from any cause
Measure: death Time: within 7 daysDescription: days since intubation
Measure: time to extubation Time: within 7 daysDescription: days from entry to exit from ICU
Measure: length of intensive care unit stay Time: within 7 daysDescription: days since CPAP initiation
Measure: time to CPAP weaning Time: within 7 daysDescription: naso-pharyngeal swab, sputum and BAL
Measure: viral load Time: at days 1, 3 and 7Description: neutralizing title
Measure: immune response Time: at days 1, 3 and 7Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports